Call for ideas to partner with GSK
GSK is calling on scientists, researchers, innovators and start-up companies to submit ideas to the Open Innovation challenge. Ideas that match specific criteria will have the chance to partner with GSK and be developed through to commericalisation.
Ideas will need to be health-related and in the areas of nutrition, wellness, oral health or skin health. Successful entrants will be provided with resources and support to potentially turn their idea into a commercial reality.
GSK has a proven track record of turning inspired product ideas into household names. For example, Sensodyne Repair and Protect toothpaste began as an initiative by two Florida dentists, who adapted US military technology for mending bones into an oral health solution. This created NovaMin which, combined with saliva and water, crystallises to form a mineral similar to natural tooth mineral. GSK saw the potential in the innovation and built a partnership with the team. Together they developed the first daily toothpaste to repair sensitive teeth, which has helped millions of people with tooth sensitivity.
GSK Innovation healthcare spokesperson Montse Pena said that GSK is excited to be promoting this opportunity to innovators in Australia and New Zealand.
“We feel certain there are bright, new healthcare product ideas in this part of the world that just need support to progress to the next level. We offer Australian and New Zealand innovators the reach, resources, scientific development and world-class marketing to help their product ideas become a commercial success.”
Submissions can be made via the Open Innovation website
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
Genes influence when babies start walking
Genetics accounts for about a quarter of the differences in when children take their first steps,...
Novel glycopeptide antibiotic candidate shows promise
Researchers have discovered a new type of glycopeptide antibiotic known as saarvienin A, found to...